Clinical trials: Tumor Pancreas
Pancreatic Cancer
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of…
- Trial name
- NCT07033689
- Testing
- Suizenji (an ultrasound-guided HIFU therapy system), Nal-IRI/FL, mFOLFIRINOX adjuvant chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- SONIRE Therapeutics Inc.
The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines
Human pancreatic cancer has a very poor prognosis with an overall survival rate of less than 5%. Current treatment regimens are ineffective and even if the patient responds to initial treatments, relapse is common due to the…
- Trial name
- CanVac (NCT04379960)
- Testing
- Peptides
- Where
- United Kingdom
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Breast Carcinoma, Colorectal Carcinoma
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04905082
- Testing
- Best Practice, Educational Intervention, Genomic Profile
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- City of Hope Medical Center
Advanced Pancreatic Cancer
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer.
- Trial name
- NCT06111274
- Testing
- Pimicotinib (ABSK021)
- Where
- 5 sites in China
- Volunteers
- 82 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Pancreas Neoplasm, Pancreas Cancer
Novel Crown-cut Biopsy Needle (FNB) vs Standard Aspiration Needle (FNA) for EUS-guided Diagnosis of SPLs
The aim of this study is to compare tissue quality and molecular yield between a novel crown-cut biopsy needle (FNB) and a standard aspiration needle (FNA) for EUS-guided diagnosis of solid pancreatic lesions.
- Trial name
- NCT04687410
- Testing
- ProControl, MediGlobe, TopGain, Medi-Globe
- Where
- Denmark
- Volunteers
- 68 people
- Sponsor
- Peter Vilmann MD, DSc, HC, FASGE
Resected Pancreatic Cancer, Pancreatic Cancer
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. Primary Endpoint: Relapse-free survival (RFS) Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
- Conditions
- Resected Pancreatic Cancer, Pancreatic Cancer, Adjuvant Chemotherapy
- Trial name
- NCT04070313
- Testing
- S-1
- Where
- 4 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- TTY Biopharm
Pancreatic Cancer
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
This multicentric randomized trial will compare the efficacy and safety of neoadjuvant chemotherapy + surgery + adjuvant chemotherapy or surgery + adjuvant chemotherapy in patients with high-risk resectable pancreatic cancer.
- Trial name
- NCT06210360
- Testing
- Irinotecan liposome injection, Oxaliplatin, 5-FU
- Volunteers
- 134 people
- Sponsor
- Changhai Hospital
Pancreatic Ductal Adenocarcinoma
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
This early phase I trial examines the safety and effects of fecal microbial transplants in treating patients with pancreatic cancer. scheduled for surgery to remove tumors.
- Trial name
- NCT04975217
- Testing
- Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Questionnaire Administration
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Pancreatic Cancer
Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial
The physical and biological properties of the carbon ion beam promise to improve the therapeutic ratio in patients with pancreatic cancer: Due to the inverted dose profile dose deposition in the entry channel of the beam leads to…
- Trial name
- PHOENIX-01 (NCT01795274)
- Testing
- Carbon Ion Radiotherapy
- Where
- Germany
- Sponsor
- University Hospital Heidelberg
Pancreas Cancer
Surgical Results of Resection of Locally Advanced Pancreatic Cancer
The aim is to compare the surgical outcomes between upfront surgery and surgery after neoadjuvant chemotherapy in terms of morbidity and mortality
- Trial name
- NCT06206382
- Testing
- Whipple operation
- Volunteers
- 80 people
- Sponsor
- Assiut University
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Advanced Solid Tumors, Metastatic Colorectal Cancer
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
The purpose of this study is to establish the safety and tolerability of BKM120 when combined with mFOLFOX6 and to define the maximum tolerated dose of BKM120 in this combination in advanced solid tumors including metastatic…
- Conditions
- Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT01571024
- Testing
- BKM120, mFOLFOX6
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and…
- Trial name
- NCT00113256
- Testing
- Rubitecan
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Pancreatic Cancer
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
- Trial name
- NCT05462496
- Testing
- Biopsy, FOLFIRINOX, Ciprofloxacin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pancreas Cancer
Evaluation of CEMIP in Pancreatic Cancer
Pancreatic cancer (PC) is one of the most lethal diseases among all cancer types. The diagnosis of PC is usually based on radiology or invasive endoscopic techniques. Various types of tumor markers are used for diagnosing PC.
- Trial name
- NCT03679910
- Testing
- CEMIP , CA19-9 ,CEA, A) CBC . B) RBG. C)KFT. D) LFT.
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Recurrent Cancer, Prostate Cancer
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
- Conditions
- Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer
- Trial name
- HETERERO (NCT04889742)
- Testing
- loco-regional hyperthermia
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Charite University, Berlin, Germany
Pancreatic Cancer
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable…
- Trial name
- NCT05604560
- Testing
- Tislelizumab, SX-682
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lei Zheng
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.